TREATMENT OF KAWASAKI DISEASE--PULSE IV METHYLPREDNISOLONE VS IVIG

川崎病的治疗--PULSE IV甲泼尼龙VS IVIG

• 批准号: 6120816
• 负责人: ROBERT SUNDEL
• 金额: $ 3.04万
• 依托单位: BOSTON CHILDREN'S HOSPITAL
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6120816
• 关键词: cardiovascular disorder diagnosis; child (0-11); clinical research; clinical trial phase I; hormone therapy; human subject; human therapy evaluation; hyperthermia; immunoglobulins; immunotherapy; intravenous administration; methylprednisolone; mucocutaneous lymph node syndrome; skin disorder diagnosis

Children diagnosed with Kawasaki disease prior to the eighth day of fever will be randomized to receive traditional therapy, intravenous immunoglobulin (IVIG) 2 g/kg over 8-12 hours, or experimental therapy, intravenous methyprednisolone (IVMP), 30 mg/kg in D5W over 2 hours on each of two consecutive days. All children will otherwise receive treatment according to current standards of care. Any child receiving either IVIG or IVMP therapy who is febrile 48 hours after treatment will receive IVIG (salvage therapy), according to current treatment guidelines.

在第八天之前被诊断出患有川崎病的儿童 发烧将被随机接受传统疗法，静脉注射 免疫球蛋白（IVIG）在8-12小时或实验疗法中2 g/kg， 静脉注射甲氧醇（IVMP），在2小时内d5W英寸30 mg/kg 连续两天中的每一个。否则所有孩子都会收到 根据目前的护理标准进行治疗。任何接收的孩子 治疗后48小时发热的IVIG或IVMP治疗将 根据目前的治疗，接受IVIG（打捞疗法） 指南。